Clinical trials located in

Candiolo

Candiolo city is located in Italy. Currently, 20 clinical trials are being conducted in this city.

Candiolo, located in the Piedmont region of Italy, is a small yet historically rich city. Known for its serene landscapes and vineyards, it offers a glimpse into traditional Italian countryside life. The city is home to the Institute for Cancer Research, a leading facility in cancer treatment and research. Candiolo’s history is marked by its medieval architecture, with the Church of San Giovanni Battista being a notable example, showcasing exquisite art and historical significance. This city embodies a blend of scientific innovation and cultural heritage.

  • CT-EU-00121249

    Study of Trabectedin for Advanced Mesenchymal Chondrosarcoma

    Mesenchymal chondrosarcoma is a rare type of cancer that affects the connective tissues in the body, often found in bones or soft tissues. This study focuses on the potential benefit of a drug called trabectedin for patients aged 16 and older who have advanced mesenchymal chondrosarcoma that has either progressed locally or spread to other parts of the body, and who have already received at least one previous chemotherapy treatment.

    The purpose of the study is to explore the activity of trabectedin in treating this specific type of cancer. Trabectedin will be given through a continuous 24-hour infusion. The dose will be determined by the investigator, with the range being from 1.3 mg/m² to 1.5 mg/m² per cycle. Each participant will receive the treatment as the only experimental therapy in the study.

    Patients will be monitored at regular intervals to assess their response to the treatment and its effectiveness over time. The study will also track any adverse effects from the treatment, aiming to understand both the potential benefits and risks of using trabectedin for this cancer type.

    The study aims to provide more information on how trabectedin works in treating mesenchymal chondrosarcoma, which could potentially lead to better treatment options for patients with this rare and challenging disease.

    • Trabectedin
  • Study of INBRX-109 for patients with unresectable or metastatic conventional chondrosarcoma

    Conventional chondrosarcoma is a type of cancer that affects the bones. This clinical trial focuses on evaluating a new treatment for patients with unresectable (inoperable) or metastatic (spread to other parts of the body) conventional chondrosarcoma. The therapy being tested is called INBRX-109. INBRX-109 is an experimental drug, specifically a humanized antibody that targets a protein called death receptor 5 (DR5). The study aims to determine whether INBRX-109 can help patients who have this type of bone cancer.

    In this study, participants will be randomly assigned to one of two groups: one group will receive INBRX-109, and the other will receive a placebo. Neither the participants nor the researchers will know who is receiving the actual drug and who is receiving the placebo. This is known as a double-blind study. Participants will receive their assigned treatment through an intravenous infusion every three weeks. If the disease progresses, those in the placebo group will be allowed to switch to the INBRX-109 treatment.

    The primary goal of the study is to see how well INBRX-109 works in preventing the cancer from getting worse. The study will also look at overall survival rates, how long any responses to the treatment last, and the quality of life of the participants during the study. Safety and tolerability of INBRX-109 will also be evaluated by monitoring for any side effects. Participants will have regular visits and tests to check on their condition and the effects of the treatment. This clinical trial offers a potential new treatment option for patients with difficult-to-treat chondrosarcoma, aiming to improve their outcomes and quality of life.

    • INBRX-109
    • placebo
  • To evaluate a combination of 3 different drugs versus 2 other drugs in the treatment of patients with melanoma

    This study compares two different approaches to treating advanced melanoma, a type of skin cancer that has spread to other parts of the body. This study is specifically aimed at patients with a gene mutation called BRAF who have previously received treatment with drugs such as nivolumab or pembrolizumab.

    One therapeutic approach involves taking three study drugs: pembrolizumab administered intravenously every 3 weeks, along with encorafenib and binimetinib taken orally daily at home. The second approach involves taking two study drugs: ipilimumab and nivolumab administered intravenously every 3 weeks for the first 4 doses, followed by nivolumab alone every 4 weeks. Both treatments will last for approximately 2 years, but there is no time limit for treatment with encorafenib and binimetinib.

    The research team will closely monitor the patients’ health during regular clinic visits to see how they are responding to treatment. The main goal is to determine which treatment method is more effective in shrinking or eliminating melanoma tumors.

    • Nivolumab
    • Ipilimumab
    • Binimetinib
    • Encorafenib
    • Pembrolizumab
  • Study on combining two drugs – Fianlimab and Cemiplimab in patients with previously untreated melanoma

    This study examines two drugs, fianlimab and cemiplimab, given together for the treatment of melanoma. The main goal is to see how effective this drug combination is in treating melanoma compared with pembrolizumab, which is already approved for the treatment of melanoma in adults. The study will also look at whether there are any differences in the effects of these experimental drugs in adolescents and adults.

    Scientists also want to learn about other key issues: what side effects may occur from taking these experimental drugs, how much of the drugs enter the bloodstream over time, and whether the body produces antibodies to the drugs that could make them less effective or cause side effects. They will also check whether taking medications improves patients’ quality of life. Fianlimab and cemiplimab will be administered by intravenous infusion, and pembrolizumab will be administered by intravenous infusion.

    • placebo
    • Fianlimab
    • Cemiplimab
    • Pembrolizumab
  • Research to enhance cancer treatments for kids and teens

    This clinical trial, known as CAMPFIRE, encompasses several studies testing new drugs for children and young adults with cancer. It includes various drug combinations such as Ramucirumab, Cyclophosphamide, Vinorelbine, Gemcitabine, Docetaxel, Abemaciclib, Irinotecan, and Temozolomide. These trials aim to evaluate the safety and effectiveness of these drugs in treating different cancer types. The study is interventional, with an estimated enrollment of 105 participants, randomized in parallel assignment. The primary purpose is treatment-focused.

    • Abemaciclib
    • Temozolomide
    • Irinotecan
    • Ramucirumab
    • Gemcitabine
    • Vinorelbine
    • Cyclophosphamide
    • Docetaxel
  • Stomach cancer treatment comparison: trastuzumab deruxtecan vs. ramucirumab & paclitaxel

    This is a thorough comparison study to measure the effectiveness and safety of two treatment paths. It’s designed for individuals who have experienced progression regarding a stomach (gastric) cancer, or cancer of the gastro-esophageal junction (GEJ). The study focuses on those with HER2-positive gastric or GEJ who have previously undergone a trastuzumab-containing regime but have not received further systemic therapy.The research compares the use of trastuzumab deruxtecan, a potent anti-cancer agent, and the combined use of ramucirumab and paclitaxel. The study’s primary goal is to evaluate the overall survival rate, while secondary aims involve examining progression-free survival, response duration, disease control, safety, pharmacokinetics, and immunogenicity.In the study, participants are fairly and randomly assigned to receive one of two treatments. This is crucial in understanding the superiority and safety of these treatment paths, and this knowledge may inform future approaches to treating these types of cancer.

    • Ramucirumab
    • Trastuzumab deruxtecan
    • Paclitaxel
  • Study on new combination therapy for aggressive lymphoma

    This study is about a less common but severe form of cancer known as Diffuse Large B-Cell Lymphoma (DLBCL). It is testing if a new medication called epcoritamab, given with a mix of other commonly used cancer medicines, can help control the disease better. These other medicines include rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone, which are often collectively referred to as R-CHOP. The study includes about 900 adults from around the world who have recently been diagnosed with this type of lymphoma. They will be split into two groups. One group will get epcoritamab with R-CHOP and then continue with epcoritamab. The other group will get R-CHOP followed by rituximab. Doctors will carefully watch for changes in the disease and for any side effects. There will be many checks on health, including medical exams, blood tests, questionnaires, and monitoring of any side effects.

    • Prednisone
    • Vincristine
    • Doxorubicin
    • Epcoritamab
    • Cyclophosphamide
    • Rituximab
  • Safety study of tafasitamab with lenalidomide for Diffuse Large B-Cell Lymphoma patients

    In this study, a novel approach to the treatment of Diffuse Large B-Cell Lymphoma (DLBCL) is being investigated. This type of cancer may have either recurred or not responded to previous treatments. The experimental intervention involves the use of two drugs: Tafasitamab, administered intravenously, and Lenalidomide, a oral medication. The study is focused on individuals who have undergone one to three prior treatments and are currently ineligible for intensive chemotherapy or a stem-cell transplant. The study is conducted in an open format, providing transparency regarding the substances being tested. Regular monitoring will be implemented to detect any potential issues and assess the concentration of the medications in participants’ blood.

    • Tafasitamab
    • Lenalidomide
  • Research on medicine combination for B-cell Non-Hodgkin Lymphoma

    This study is about testing epcoritamab, a new drug for a type of blood cancer called B-cell Non-Hodgkin Lymphoma. The goal is to see if the drug is safe for people and can successfully fight the cancer. Doctors will combine this drug with other medicines that are typically used to treat this cancer. The combined treatment will vary for different groups of patients, depending on factors like their specific type of cancer or their overall health. Some patients will be given epcoritamab on its own, while others will receive it with other cancer medicines. The study has two parts. The first part is to find a safe dose of the drug. The second part is to determine how well this drug helps in treating the cancer. Side effects will be closely monitored during the study.

    • etoposide phosphate
    • oxaliplatin
    • Prednisone
    • Dexamethasone
    • Carboplatin
    • Epcoritamab
    • Ifosfamide
    • Cytarabine
    • Gemcitabine
    • Cyclophosphamide
    • Vincristine
    • Doxorubicin
    • Bendamustine
    • Lenalidomide
    • Rituximab
  • Study of trastuzumab deruxtecan in gastric cancer or gastroesophageal junction adenocarcinoma

    The aim of the DESTINY-Gastric04 study is to help cancer patients suffering from certain diseases. These patients have a specific type of stomach cancer or adenocarcinoma of the gastroesophageal junction that has not responded to treatment or has gotten worse after treatment with a medicine called trastuzumab. This study is testing a new drug called trastuzumab deruxtecan, comparing it with a combination of two other drugs – ramucirumab and paclitaxel. A key goal of this study is to determine how long participants will live after starting a new treatment. It will also be observed whether the cancer will shrink or stop growing, how long it will last, what the potential side effects of treatment will be and how the body will respond to the new drug.

    • Ramucirumab
    • Trastuzumab deruxtecan
    • Paclitaxel
  • Testing zimberelimab and domvanalimab with chemotheraphy for lung cancer

    This clinical trial explores the effectiveness of two new medicines, zimberelimab and domvanalimab, in tandem with chemotherapy for patients with untreated metastatic non-small cell lung cancer. The study’s main goal is to compare the impact and success of this combination treatment versus a control group receiving pembrolizumab along with chemotherapy. The hopeful outcome of the trial is to identify whether the new combination of drugs can provide enhanced benefits for the involved patients. Regular health monitoring will occur during the trial to ensure patient safety.

    • Pemetrexed
    • Nab-paclitaxel
    • Paclitaxel
    • Cisplatin
    • Carboplatin
    • Pembrolizumab
    • Domvanalimab
    • Zimberelimab
  • Pemigatinib in the treatment of cholangiocarcinoma

    This study focuses on comparing the impact and safety of two treatments: Pemigatinib and a chemotherapeutic combination of Gemcitabine and Cisplatin. These treatments are being tested on people who have an advanced form of liver cancer, cholangiocarcinoma, which cannot be removed by surgery or has spread to other parts of the body, and is associated with a particular genetic change known as FGFR2 rearrangement. The aim is to examine the effectiveness of Pemigatinib in comparison to the chemotherapy combination of Gemcitabine and Cisplatin. Measurements of success will be based on how much the cancer shrinks, the duration of response to treatment, as well as any side effects encountered.

    • Pemigatinib
    • Gemcitabine
    • Cisplatin
  • Monitoring the long-term safety of Nivolumab for cancer survivors

    This study is designed to understand the long-term effects of a medicine called Nivolumab in patients who have fought against various forms of cancer. In this study, the focus is on closely examining the long-term efficiency and safety of Nivolumab. Participants in the investigation encompass both current and past users of Nivolumab.

    • Nivolumab
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    • Zanubrutinib
    • Obinutuzumab
    • Lenalidomide
    • Rituximab
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    • Dazostinag
    • Platinum
    • Pembrolizumab
    • 5-Fluorouracil
  • Exploring new vs usual treatment for bladder cancer

    This clinical trial is testing a new combination of two drugs, Gemcitabine Hydrochloride (TAR-200) and Cetrelimab, with people who have a certain type of bladder cancer called Muscle invasive bladder cancer (MIBC). The study aims to see if these drugs work better than the usual treatment of chemotherapy and radiation therapy. The goal is to see which one keeps the bladder cancer-free for longer. Doctors also follow up with patients to record any side effects from the treatments.

    • Gemcitabine Hydrochloride/TAR-200
    • Cetrelimab
    • Gemcitabine
    • Cisplatin
  • Trial for advanced solid tumors with specific mutation: safety and effectiveness study

    This study focuses on evaluating the safety and effectiveness of combining two drugs, INCB099280 and Adagrasib, in treating adults with advanced solid tumors having a specific mutation (KRASG12C). It is an intervention-based trial with 125 participants, aimed at finding the right dosage and understanding the treatment’s impact. The study is open to individuals with certain types of cancer, including lung and colorectal cancer, who meet specific criteria. The main goals are to assess safety, treatment response, and disease control.

    • Adagrasib
    • INCB099280- new potential medication for solid tumors
  • Discovering new treatments for breast cancer with trastuzumab deruxtecan

    This clinical trial is evaluating a new treatment, Trastuzumab Deruxtecan (T-DXd), for early-stage, HER2-positive breast cancer. The study compares T-DXd alone or in sequence with other treatments against the standard therapy. It’s designed for patients with high-risk, non-metastatic breast cancer and aims to find out if T-DXd is more effective and safe. The focus is on how well patients respond to the treatment and their overall and disease-free survival rates.

    • Doxorubicin
    • Trastuzumab deruxtecan
    • Cyclophosphamide
    • Trastuzumab
    • Pertuzumab
    • Paclitaxel
  • Trial for new lung cancer treatment

    This study evaluated the effectiveness of telisotuzumab Vedotin, an investigational drug, in adults with a specific type of lung cancer called non-squamous non-small cell lung cancer (NSCLC), which has MET amplification. Participants will receive the drug as an intravenous infusion every two weeks and will be closely monitored for changes in tumor activity. The study will involve patients with this particular type of lung cancer, focusing on those that have not been previously treated due to advanced or metastatic disease. Regular medical evaluations, blood tests and monitoring for side effects are part of a study to understand the effects of the drug.

    • Telisotuzumab Vedotin
  • Study of new drugs in acute lymphoblastic leukemia

    This clinical trial focuses on improving treatment strategies for acute lymphoblastic leukemia (ALL) in a diverse age group, from infants to young adults up to 45 years old. The study combines standard treatments with new drugs, for example, Inotuzumab Ozogamicin and Blinatumomab. The trial aims to tailor treatment to individual patient needs and reduce toxicity while maintaining treatment quality. By carefully monitoring event- and disease-free survival rates, as well as minimal residual disease responses, the trial aims to improve the standard of care for ALL and improve both survival outcomes and patient quality of life.

    • Inotuzumab Ozogamicin
    • 6-tioguanine
    • Blinatumomab
    • Imatinib
    • Dexamethasone
    • Vincristine
    • Doxorubicin

See more clinical trials in other cities in Italy:

.